Overview

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Status:
Withdrawn
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Karyopharm Therapeutics Inc